Loading viewer...
investor_presentation
Format: PDF investor_presentation
Teladoc Health investor presentation dated December 2021.
4Q-21 Quarterly Results
••4Q Revenue of $554M grew 45% y/y
•4Q Adjusted EBITDA(1)of $77.1M grew 53% y/y
•FY-21 Operating Cash Flow of $194M
•FY-22 Revenue guidance range $2.55B to $2.65B
•1Q-22 Revenue guidance range $565M to $571M
•FY-22 Adj. EBITDA guidance range $330M to $355M
•1Q-22 Adj. EBITDA guidance range $51M to $55M
1. See reconciliation of GAAP to non -GAAP measures immediately following this presentation.$50.4$77.1
$0$10$20$30$40$50$60$70$80$90
4Q-20 4Q-21Adj. EBITDA ($ millions)(1)
$0$100$200$300$400$500$600
4Q-20 4Q-21Revenue ($ millions)
1.See reconciliation of GAAP to non -GAAP measures immediately following this presentation+53%
y/yAccess Fee Revenue ($ millions) (1)Visit Fee Revenue ($ millions) (1)
$0$100$200$300$400$500
$0$10$20$30$40$50$60$70$80
1. During the fourth quarter of 2021, Teladoc Health refined its definition of international revenues to reflect all internation al revenues based on location of the customer. Previously, direct to consumer activities
were primarily reflected based on the location of operations. In addition, certain activities related to our international op erations are now reflected in visit revenues versus access fee revenues. Prior period
amounts have been recast to conform with current presentation. Consistent with this change, the corresponding metrics have be en updated.$51$71
$0$10$20$30$40$50$60$70$80
$0$100$200$300$400$500$600
4Q-20 4Q-21U.S. Revenue ($ millions) (1)International Revenue ($ millions) (1)
1. During the fourth quarter of 2021, Teladoc Health refined its definition of international revenues to reflect all internation al revenues based on location of the customer. Previously, direct to consumer activities
were primarily reflected based on the location of operations. In addition, certain activities related to our international op erations are now reflected in visit revenues versus access fee revenues. Prior period
amounts have been recast to conform with current presentation. Consistent with this change, the corresponding metrics have be en updated.U.S. Paid Members (millions) Revenue ($ millions) (1)
Avg US Revenue per Member (1) (2) Chronic Care Enrollment (000s)
1. During the fourth quarter of 2021, Teladoc Health refined its definition of international revenues to reflect all internation al revenues based on location of the customer. Previously, direct to consumer activities were
primarily reflected based on the location of operations. In addition, certain activities related to our international operati onsare now reflected in visit revenues versus access fee revenues. Prior period amounts have
been recast to conform with current presentation. Consistent with this change, the corresponding metrics have been updated.
Preview truncated — download the full document for the complete content.
conference
24 Pages
Teladoc Health Investor Presentation — August 2022
investor_presentationinvestor_presentation
11 Pages
investor_presentation
22 Pages
Acreage Holdings
South Harz Potash 2023 Investor Presentation
investor_presentationinvestor_presentation
28 Pages
South Harz Potash Limited